GSK’s announcement of a £400 million investment in a new global research and development centre on the Cambridge Biomedical Campus is excellent news for the United Kingdom. It reinforces Cambridge’s position as one of the world’s foremost centres for biomedical research and underlines the confidence that major international companies continue to place in British science.

Yet the announcement also highlights a much bigger question. Are we recognising that life sciences are entering a new era, one in which the medicines of tomorrow will look fundamentally different from those that have transformed healthcare over the past century?

For generations, the pharmaceutical industry has been built upon the discovery, manufacture and distribution of medicines designed for millions of patients. Whether antibiotics, vaccines, cardiovascular drugs or cancer treatments, these medicines have saved countless lives and will continue to do so. They remain an essential foundation of modern healthcare.

Alongside this established model, however, a second revolution is rapidly emerging.

Cell and Gene Therapies are changing the very nature of medicine. Rather than treating symptoms or slowing disease progression, many of these therapies are designed to correct the underlying biological cause of disease. Increasingly, they are personalised for individual patients, using their own cells or precise genetic interventions to restore normal function.

This represents a profound shift in medical science. The focus is moving from mass-produced medicines towards precision treatments capable of tackling conditions once considered incurable.

This is where Stevenage occupies a unique position.

Over the past decade, Stevenage has quietly become one of the world’s leading centres for Cell and Gene Therapy development. The Cell and Gene Therapy Catapult, Stevenage Bioscience Catalyst and a growing cluster of pioneering biotechnology companies have created an internationally recognised ecosystem where research, clinical development, manufacturing and commercialisation exist side by side.

This capability is not in competition with Cambridge. It is its natural partner.

Cambridge excels in world-class scientific discovery, academic excellence and clinical research. Stevenage provides the expertise to translate many of those discoveries into advanced therapies that can be manufactured safely, efficiently and at commercial scale for patients across the world.

Together they create something few countries can match: a complete innovation pathway from laboratory discovery to patient treatment.

As Government continues to develop its Industrial Strategy and Life Sciences Vision, it should resist concentrating attention on a single location, however successful. Instead, it should champion a Cambridge–Stevenage innovation corridor that combines discovery science with advanced therapy development and manufacturing.

Britain already possesses the ingredients to become the global leader in next-generation medicine. Cambridge provides the ideas. Stevenage provides the pathway to delivering them to patients.

The future of healthcare will not be built by choosing between pharmaceuticals and personalised therapies. It will be built by recognising that both are essential—and by ensuring that Britain’s investment strategy reflects the complementary strengths of each.

If Cambridge discovers tomorrow’s breakthroughs, Stevenage can help turn them into tomorrow’s cures.